Abdul Qayyum

Full court resumes hearing petitions challenging Supreme Court (Practice and Procedure) Act 2023

ISLAMABAD: As the hearing of petitions against the Supreme Court Act 2023 resumed on Monday, Chief Justice of Pakistan Qazi Faez Isa asked if the Parliament can correct a mistake made by the...

CJP Qazi Faez Isa is presiding the full-court bench hearing comprising all judges of Supreme Court

ISLAMABAD: Justice Munib Akhtar of the Supreme Court on Tuesday said that asking questions from a petitioner is his prerogative after Chief Justice Qazi Feaz Isa called for letting a lawyer complete...

You are last but not the least, Chief Justice of Pakistan (CJP) Qazi Faez Isa tells AGP Awan

Full court upholds Supreme Court (Practice and Procedure) Act 2023

Petition filed in wake of apex court ruling on Practice and Procedure Act 2023

Actin dynamics is pivotal in controlling cotton fiber elongation and the onset of secondary wall biosynthesis. We report that overexpression of GhACTIN1 under fiber fiber-specific promoter, GhSCFP, improves cotton fiber length, strength, and micronaire value. However, the effect of transgene has a more positive effect on fiber strength and micronaire value than fiber length. F-actin quantification and cellulose contents measurement in transgenic developing cotton fiber during the elongation phase showed an increase of up to 8.7% and 4.7% respectively. Additionally, physiological factors such as water use efficiency showed no significant change in transgenic cotton lines, while stomatal conductance and photosynthetic rate were significantly increased. Moreover, agronomical data determined that lint percentage (GOT) and seed cotton yield also increased up to 4.6% and 29.5% respectively, in transgenic cotton lines compared to the control lines. Our data demonstrate that the GhACTIN1 gene is a strong candidate gene for cotton fiber and yield improvement.

Background and aim: While proton pump inhibitor (PPI) therapy has proven to be effective in managing gastroesophageal reflux disease (GERD), a notable portion of patients who experience GERD symptoms may not respond to this treatment. Research suggests that roughly 30% of individuals with a presumed GERD diagnosis may continue to experience symptoms, whether partially or completely, even when receiving PPI therapy. The aim of this study was to assess the treatment of gastrointestinal diseases with a novel potassium-competitive acid blocker (P-CAB), vonoprazan, in terms of its effectiveness and safety in the Pakistani population.Methods: This prospective, multicenter, observational study was conducted in Pakistan. This study included 1,642 patients from January 2023 to August 2023, aged 18 years, with gastrointestinal disorders. All demographic data, medical history, GERD severity assessment questionnaire (GerdQ), and laboratory parameters, including stool assessment for Helicobacter pylori (H. pylori), were observed. Patients were orally treated with vonoprazan at doses of 10 mg or 20 mg, once or twice daily. Statistical analysis was done by one-way ANOVA.Results: Out of 1,642 patients, 840 (51.2%) were males and 802 (48.8%) were females, with a mean age of 39.81±14.61 years. The mean GerdQ score at baseline was 20.37±15.87, 7.24±8.15 at the second week of treatment, and 3.70±6.31 at the fourth week of treatment (p70% of days. Most of the patients, 1,283 (78.13%), exhibited good treatment compliance. Mild adverse events were reported in 37 (2.3%) patients.Conclusions: The use of vonoprazan significantly reduced the likelihood of GERD by improving symptoms and was also highly effective in the elimination of H. pylori infections. Vonoprazan was generally well tolerated.

Namra Naseer , Fatima Khurshid , Yumna Khan , Rabail Taj , Abdul Qayyum Medical Doctor, Department of Oncology, Bait ul Sukoon – Cancer Hospital and Hospice, Pakistan